



Technical Report No. 73

Prefilled Syringe User Requirements for Biotechnology Applications



PDA Prefilled Syringe User Requirements for Biotechnology Applications Technical Report Team

Authors and Contributors

Ron Forster, Ph.D., Amgen, Team Leader	Alice Maden, Becton Dickinson
Ross Allen, Eli Lilly and Company	Mary Mathieu, AbbVie
Khandan Baradaran, Dimension Therapeutics	Kingman Ng, Ph.D., Novartis
Sherri Biondi, Genentech	QuynhNhu Nguyen, U.S. FDA / CDRH
Alfred Breunig, Nipro Glass Germany AG	Thomas Nikolai, Hospira
Charlene Brisbane, GlaxoSmithKline	Carlos Ortiz, Eli Lilly and Company
Anil Busimi, Schott	Bruno Reuter, Nipro Europe NV
Rey Chern, Ph.D., Amgen	Julio Rivera, SiO2 Medical Products
Piet Christiaens, Ph.D., Toxikon Europe NV	Lesbeth C. Rodriguez, Bayer Healthcare Pharmaceuticals, Inc
Jean-François DeCoster, UCB Pharma S.A.	Andrea Salmaso, Pharma.D., Stevanato Group spa
Andrew Donnelly, Bespak	Thomas Schönknecht, SHL
Peter Gassmann, Ph.D., Johnson & Johnson	Jörg Sielemann, F. Hoffmann La Roche AG
Aarti Gidh, Ph.D., GlaxoSmithKline	Hervé Soukiassian, Becton Dickinson
Heike Gruen, West Pharmaceutical Services	Kalavati Suvarna, Ph.D., U.S. FDA
Olivia Henderson, Ph.D., Biogen	Robert Swift, Ompi
Carl Hitscherich, Ph.D., Biogen	Randy Thackrey, Eli Lilly and Company
Tibor Hlobik, West Pharmaceutical Services	Raja Thyagarajapuram, Ph.D., Eli Lilly and Company
Colleen Hutter, Merck	Simon Toth, Dow Corning Corporation
Renaud Janssen, Datwyler Pharma Packaging Belgium NV	Li-Chun Tsou, Ph.D., AstraZeneca
Laurent Jeanmart, Ph.D., GlaxoSmithKline Biologicals	Tina Tubbs, Sanofi-Pasteur
Akshay Kamdar, Ph.D., Eli Lilly and Company	Paulo Villaneuva, Genentech
Suzanne Kiani, Amgen	Lee Wood, F. Hoffmann La Roche AG
James Kershner, Eli Lilly and Company	Jörg Zimmermann, Vetter Pharma
Lei Li, Ph.D., Eli Lilly and Company	Daniele Zuccato, Stevanato Group spa

DISCLAIMER: The content and views expressed in this Technical Report are the result of a consensus achieved by the authorizing Technical Report Team and are not necessarily views of the organizations they represent.

Prefilled Syringe User Requirements for Biotechnology Applications

Technical Report No. 73

ISBN: 978-0-939459-82-7

© 2015 Parenteral Drug Association, Inc.

All rights reserved.



www.pda.org/bookstore

Table of Contents

1.0 INTRODUCTION	1	5.0 EXTRACTABLES AND LEACHABLES EVALUATION	24
1.1 Purpose/Scope.....	1	5.1 Production of Syringe Barrels	24
2.0 GLOSSARY OF TERMS	3	5.1.1 Cutting Step (Horizontal forming)	25
3.0 PREFILLED SYRINGE DEVELOPMENT AND LICENSING.....	6	5.1.2 Forming Step (Horizontal/Vertical forming)	25
3.1 High-Level Overview of Key System Functions	6	5.1.3 Needle Assembly Step.....	25
3.1.1 Key System Function: Treating the Patient	6	5.1.4 Washing, Siliconization, Needle-Shield Positioning, and Packaging.....	25
3.1.2 Key System Function: Enabling Market Approval	6	5.2 Ethylene Oxide and Gamma Irradiation Sterilization and Decontamination Processes....	26
3.1.3 Key System Function: Enabling Production and Distribution of the Delivery System.....	7	5.3 Sources of Extractable and Leachable Substances	26
3.2 Regulatory Considerations	8	5.3.1 Elastomeric Components	27
3.2.1 Manufacturer Considerations.....	8	5.3.2 Glass Components	27
3.2.2 Supplier Considerations for Filing.....	8	5.4 Extraction Conditions and Sample Preparation.....	28
3.2.3 Healthcare Provider Instruction for use of PFSs	9	5.5 Analytical Methodology	29
3.2.4 Regulatory Submission Content for PFS Combination Products.....	10	5.6 Data Evaluation.....	31
3.2.5 Standards and Technical References Applicable to PFS.....	11	5.7 Threshold Evaluation.....	31
4.0 PFS HUMAN FACTORS ENGINEERING.....	12	5.8 Conclusion	32
4.1 Current Standards and Guidance	12	6.0 GLASS BARREL REQUIREMENTS	34
4.2 Human Factors Evaluation	14	6.1 Flange Geometry	34
4.3 Device-Use Characterization	14	6.1.1 Finger Flange Thickness.....	34
4.3.1 User Populations	14	6.2 Flange Strength	34
4.3.2 Use Environment.....	15	6.3 Barrel Geometry	35
4.3.3 Intended Use Scenarios	15	6.4 Syringe Shoulder Design: Impact on Hold-up Volume.....	35
4.4 Defining User Needs	15	6.5 Additional Considerations.....	36
4.5 Design Requirements.....	16	7.0 NEEDLE REQUIREMENTS	37
4.6 Risk Management.....	16	7.1 Minimizing Injection Site Events	37
4.6.1 Hazard Identification	16	7.1.1 Needle Geometry	38
4.6.1.1 Literature Search.....	16	7.1.2 Needle Lubrication	40
4.6.1.2 Empirical Research.....	17	7.1.3 Needle Defects	40
4.6.1.3 Analytical Use Error Identification Methods.....	17	7.2 Material Compatibility with Drug Products	41
4.6.2 Use-Related Risk Analysis	17	7.3 Conclusion	41
4.6.2.1 Essential and Safety-Critical Task Identification	18	8.0 NEEDLE-SHIELD REQUIREMENTS	42
4.6.2.2 Common PFS Use-related Hazards.....	19	8.1 Functions of the Needle Shield	42
4.7 Formative Usability Evaluation.....	20	8.2 Material Property Requirements	43
4.8 Summative/Validation Testing.....	21	8.2.1 Needle-Shield Extractables Profile	44
4.9 Labeling	22	8.2.2 Needle-Shield Leachables Profile	44
4.10 Changes to Currently Marketed Products	23	8.2.3 Needle-Shield E-beam Compatibility	44
		8.2.4 Needle-Shield Elastomer Cleanliness	44

8.3 Mechanical Property Requirements.....	45	11.4 Plunger Rod/Plunger Stopper Interactions	65
8.3.1 Needle-Shield Pull-off Force.....	45	11.5 Plunger Stopper Suitability: Hold-up Volume	66
8.3.2 Influence of Needle Shield on Needle Sharpness	45	11.6 Dimensional Control	66
8.4 Container Closure Integrity Requirements	45	11.6.1 Defining Critical Plunger Stopper Dimensions.....	66
8.4.1 Empty Syringe.....	45	11.6.2 Plunger Stopper Dimensional Control at Component Manufacturer Site.....	66
8.4.2 Filled Syringe throughout the Life Cycle.....	46	11.6.3 Sampling Plans and Acceptance Sampling System for End User Incoming Inspection Site	67
8.5 Dimensional Requirements.....	46	11.6.4 Dimensional Measurement Methods and Harmonization.....	67
9.0 COSMETIC IMPERFECTIONS	47	11.7 Product Interactions	67
9.1 Defect Identification	48	11.8 Secondary Packaging	67
9.2 Defect Classification.....	48	11.9 Shelf Life and Storage	69
9.3 Visual Inspection of Unfilled Syringes.....	49	11.10 Processing Interactions (Plunger Stopper Design vs. Equipment Requirements)	69
9.3.1 Manual Visual Inspection	49	11.10.1 Elastomer Selection.....	69
9.3.2 Automated Visual Inspection	49	11.10.2 Surface Treatments	69
10.0 SILICONIZATION	51	11.10.3 Plunger Stopper Dimensions.....	70
10.1 Type of Silicone and Areas of Application.....	51	11.11 Plunger Stopper Geometry.....	70
10.1.1 Empty Staked needle Syringe Barrel.....	51		
10.1.2 Effects of Fixed-nozzle Systems	52		
10.1.3 Effects of Diving Nozzle Systems.....	53		
10.2 PFS Barrel and Plunger Stopper Combination	54		
10.3 PFS Barrel and Needle-Shield Combination	55		
10.4 Siliconization of the Injection Needle.....	55		
10.5 Drug Product Requirements.....	55		
10.6 Shelf-life Effects	55		
10.7 Methods Toolbox.....	55		
10.7.1 Fourier Transform Infrared Spectroscopy.	56		
10.7.2 Powder Tests	56		
10.7.3 Reflectometry Measurements	57		
10.7.4 Schlieren Effect Analysis	57		
10.7.5 Break-loose and Extrusion Force	58		
10.8 Measuring Silicone Oil in Solutions	58		
10.8.1 Subvisible Particle Analysis	59		
11.0 PLUNGER STOPPER SUITABILITY	60		
11.1 Materials, Coatings, and Laminates	60		
11.1.1 Formulations.....	60		
11.1.2 Laminates and Coatings	61		
11.2 Function of Processing and Sterilization	62		
11.2.1 Bulk	62		
11.2.2 Presterilized Plunger Stoppers	62		
11.2.3 Sterilization.....	63		
11.3 Functional Properties.....	63		
11.3.1 Seal Integrity	63		
11.3.2 Extrusion Behavior.....	65		
12.0 CONTAINER CLOSURE INTEGRITY REQUIREMENTS	71		
12.1 Regulatory Basis for Container Closure Integrity	71		
12.2 PFS Design Issues	72		
12.2.1 Plunger Stopper/Barrel Interface.....	72		
12.2.2 Barrel/Needle-Shield Interface	72		
12.2.3 Needle-shield/Needle Interface.....	72		
12.3 Supplier and Pharmaceutical Processes	73		
12.3.1 Supplier Components, Subassembled Components, and Component Packaging and Distribution	73		
12.3.2 Incoming Receipt and Inspection.....	73		
12.3.3 Semifinished Syringes	74		
12.3.4 Syringe Assembly and Secondary Packaging	74		
12.3.5 Shipping and Distribution of Semifinished Syringes and PFSs	75		
12.4 CCI Test Method Toolbox: Method Selection, Development, and Validation.....	75		
13.0 MANUFACTURING REQUIREMENTS	77		
13.1 Component Packaging from the Component Manufacturer.....	77		
13.1.1 Packaging of Presterilized Syringe Systems	77		

13.1.1.1 Nest.....	77
13.1.1.2 Tub	78
13.1.1.3 Tyvek® sheet and Tyvek® lid.....	78
13.1.1.4 Steribag.....	78
13.1.1.5 External Box	79
13.1.2 Presterilized Component Sterilization.....	79
13.1.3 Bulk Syringes.....	79
13.1.4 Rondo Trays: Materials, Dimensions, and Designs.....	79
13.1.4.1 Secondary Packing of Rondo Trays	80
13.2 Machinability.....	80
13.2.1 Filling of Presterilized Syringes (tub-nest configuration)	80
13.2.2 Electron Beam Tunnel	80
13.2.3 Hydrogen Peroxide Pass-through Locks	81
13.2.4 Low-Pressure Plasma	81
13.2.5 Alcohol Wipe Disinfection Followed by Automatic Bag Opening and Transfer	81
13.3 Filling of Bulk Syringes	83
13.4 Visual Inspection	84
13.4.1 Semiautomated Visual Inspection	84
13.4.2 Automated Visual Inspection.....	84
13.5 Final Drug Assembly and Product Secondary Packaging	85
13.5.1 Labeling, Plunger Rod, and Backstop Placement.....	85
13.5.2 Blistering	86
13.5.3 Cartoning	86
13.5.4 Bundling and Palletizing.....	86
13.5.5 Special Considerations for Serialization	86
14.0 DRUG PRODUCT COMPATIBILITY	87
14.1 Risk Assessment.....	87
14.2 Key Product and Manufacturing Attributes	88
14.2.1 Stability Studies	88
14.2.2 Analysis of Stability.....	89
14.2.2.1 Force Measurements	90
14.2.2.2 Special Considerations: the Effect of Silicone on Analytical Testing, Including Particle Analysis	90
14.3 Compatibility of the Drug Product with the Plunger Stopper and Needle Shield	91
14.3.1 Impact of Interaction between the Drug Product and Rubber in the Needle Shield	91
14.3.2 Impact of Interaction between the Plunger Stopper and Drug product.....	91
14.3.3 Needle Shield Permeability	92
14.4 Needle Passage Shear.....	92
14.4.1 Experimental Design.....	92
14.5 Compatibility with Process Intermediates and Additives	93
14.6 Types of Silicone	93
14.6.1 Silicone Compliance with Monographs...	93
14.6.2 Effects of Extractables on Products	94
14.6.2.1 Tungsten.....	94
14.7 Process-related Compatibility and Stability	94
14.8 Shock, Vibration, and Shipping Study.....	94
15.0 APPENDIX I: ELECTRONIC COMMON TECHNICAL DOCUMENT (ECTD) APPLICATION SUBMISSION OVERVIEW	96
16.0 APPENDIX II: MODULE 3 FOR ELECTRONIC COMMON TECHNICAL DOCUMENT (ECTD) SUBMISSION OVERVIEW	97
17.0 APPENDIX III: TESTS, STANDARDS, AND GUIDANCE DOCUMENTS FOR PFS COMBINATION PRODUCTS	99
18.0 APPENDIX IV: COMPOUND CLASSIFICATION WITH THE ASSOCIATED THRESHOLD OF TOXICOLOGICAL CONCERN (TTC)	102
19.0 REFERENCES.....	103

FIGURES AND TABLES INDEX

Figure 1.1-1	Schematic drawing of a PFS..... 2	Figure 10.7.2-1	Siliconization with Fixed Nozzles... 56
Table 3.1.3-1	Overview of interactions Between key system functions & Components in the PFS Life Cycle . 7	Figure 10.7.2-2	Siliconization with Diving Nozzles... 56
Table 4.1-1	Human Factors Engineering-Related Standards and Guidances 13	Figure 10.7.3-1	Radial Silicone Oil Distribution Measurement 57
Table 4.6.2.2-1	Examples of Common Use-Related Hazards and Harms Associated with PFS 20	Figure 10.7.4-1	Silicone Oil Droplet Visualization.. 58
Table 5.4-1	Extraction study types 28	Table 11.1.1-1	Elastomer Components and Target Properties..... 60
Table 5.4-2	Potential extraction study considerations 29	Table 11.1.2-1	Typical 1 mL long syringe plunger stopper coatings and laminate films 61
Table 5.5-1	Analytical Techniques for Extractables and Leachables Evaluation 30	Table 11.1.2-2	Plunger stopper Coating Options... 62
Figure 6.4-1	Glass Syringe Cone with Needle Inserted 35	Figure 11.2.3-1	Generalized Bulk Sterilization Process..... 63
Figure 7.0-1	Syringe component diagram..... 37	Figure 11.3.2-1	Gliding Curves of Two Plungers in the Same Type of Syringe Barrel.. 65
Figure 7.1.1-1	Needles with Three- or Five-Bevel Tips 38	Figure 11.4-1	Plunger Rod 66
Figure 7.1.1-2	Exposed Portion of Needle 39	Figure 11.5-1	Plunger Stopper with Lightly Tapered Tip 66
Figure 7.1.3-1	Scanning electron micrograph of a needle hook 41	Figure 11.8-1	Examples of Sterilized Plunger stoppers in Secondary Packaging .. 68
Figure 8.1-1	Nonrigid (soft) Needle Shield (L) and Rigid Needle Shield (RNS) (R).. 42	Figure 12.2-1	Syringe component interfaces involved in CCI..... 72
Figure 9.0-1	PFS Assembly Steps 47	Table 12.4-1	Comparison of CCI Testing Methods 76
Table 9.0-1	Available Guidance and standards for PFS components.... 47	Table 13.1.1-1	Packaging Methods 77
Figure 9.2-1	Sample needle defects 48	Figure 13.1.1.4-1	Steribag Components 78
Figure 9.3.2-1	Example of Automated Visual Inspection of an Empty Glass Barrel 50	Figure 13.1.1.5-1	Packaging Configuration 79
Figure 10.1.2-1	Fixed-Nozzle Siliconization (injected mass 0.8 mg, image based on ZebraSci® system) 52	Figure 13.1.4-1	Rondo Tray..... 80
Figure 10.1.2-2	Fixed-Nozzle Siliconization – Break- Loose and Gliding Force Profile.... 53	Table 13.2.5-1	Process for Filling Presterilized Syringes..... 82
Figure 10.1.3-1	Diving Nozzle Siliconization (image based on ZebraSci® system) 53	Table 13.3-1	Process for Filling Bulk Syringes.. 83
Figure 10.1.3-2	Diving Nozzle Siliconization: Optimal Break-loose and Gliding Force Profile..... 54	Table 13.4-1	Examples of Post-Filling Visual Inspection Defects..... 84
		Table 14.1-1	Example of Risk Assessment Output..... 88
		Table 14.2.1-1	Outline of Typical Stability Studies Used to Assess PFSs..... 89
		Table 14.2.2-1	Stability analysis for PFS Contents 90
		Table 14.6-1	Types of Silicone..... 93
		Table 14.6.1-1	Typical Silicone Oils Tests..... 94